Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 13/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | TYMS | P04818 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28041457 | 0.77 | MAOA (0.56) | BRD4CYP2A6MAOAMAOBADRB2 | |
| SCHEMBL16555857 | 0.77 | BCL2L1 (0.42) | CYP2A6MAOAMAOBTSHR | |
| SCHEMBL29501042 | 0.76 | PARP1 (0.55) | BRD4CYP2A6MAOAMAOBADRB2 | |
| SCHEMBL1151194 | 0.76 | PARP1 (0.55) | BRD4CYP2A6MAOAMAOBADRB2 | |
| SCHEMBL7102610 | 0.76 | KEAP1 (0.47) | CYP2A6MAOAMAOBADRB2ADRB1 | |
| SCHEMBL23815139 | 0.75 | ALDH1A1 (0.32) | MAOB | |
| SCHEMBL14193725 | 0.75 | ALDH1A1 (0.32) | MAOB | |
| SCHEMBL12251267 | 0.74 | CYP2A6 (0.44) | BRD4CYP2A6MAOAMAOBADRB2 | |
| SCHEMBL15461569 | 0.73 | BCL2L1 (0.47) | TSHR | |
| SCHEMBL16745636 | 0.72 | TYMS (0.39) | TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1304380-C | Benzo[a]henazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II | XENOVA LTD (GB) | 2007-03-14 | — | — | CN | disclosed |
| US-7132419-B2 | Pharmaceutical compounds | XENOVA LIMITED (GB) | 2006-11-07 | — | — | US | disclosed |
| US-20050143383-A1 | Pharmaceutical compounds | XENOVA LIMITED (GB) | 2005-06-30 | — | — | US | disclosed |
| CN-1433406-A | Benzo [ a ] phenazine-11-amide derivatives and their use as combined topoisomerase I and II inhibitors | XENOVA LTD (GB) | 2003-07-30 | — | — | CN | disclosed |
| US-20030139409-A1 | Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II | XENOVA LIMITED (GB) | 2003-07-24 | — | — | US | disclosed |
| EP-1240148-A1 | BENZO[A]PHENAZIN-11-CARBOXAMIDE DERIVATIVES AND THEIR USE AS JOINT INHIBITORS OF TOPOMERASE I AND II | Xenova Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001046157-A1 | BENZO[A]PHENAZIN-11-CARBOXAMIDE DERIVATIVES AND THEIR USE AS JOINT INHIBITORS OF TOPOMERASE I AND II | XENOVA LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143383-A1 | Pharmaceutical compounds | CHRNA10, OPRM1, SCN10A | BRD4 1244/4885CYP2A6 127/4885MAOA 1921/4885 |
| US-20030139409-A1 | Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II | TOP1, TOP2A, TOP2B | BRD4 1260/4885CYP2A6 34/4885MAOA 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.